Insulinoma differential diagnosis

Revision as of 14:56, 5 December 2017 by Damola (talk | contribs) (→‎Overview)
Jump to navigation Jump to search

Insulinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Insulinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

X-ray

Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Insulinoma differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Insulinoma differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Insulinoma differential diagnosis

CDC on Insulinoma differential diagnosis

Insulinoma differential diagnosis in the news

Blogs on Insulinoma differential diagnosis

Directions to Hospitals Treating Insulinoma

Risk calculators and risk factors for Insulinoma differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]

Overview

Insulinoma must be differentiated from other diseases that cause features of hypoglycemia like altered mental status/confusion, profuse sweating and visual disturbances (blurring/diplopia). These are classified on the basis of laboratory findings into exogenous insulin, oral hypoglycemic agents (e.g. Sulphonylureas), Nesidioblastosis, insulin autoimmune hypoglycemia.

Differentiating insulinoma from other Diseases

Insulinoma must be differentiated from other diseases that cause features of hypoglycemia. These are classified on the basis of laboratory findings.

Differentials for Hypoglycemia on the basis of Laboratory findings:[1]

Diagnoses Laboratory Findings differentiating among causes of Hypoglycemia
S.Glucose
(mg/dL)
C Peptide (pmol/L) S.Insulin (μU/mL) S.Proinsulin
(pmol/L)
S. Beta hydroxybutyrate Glucose increase after glucagon(mg/dL) Oral Hypoglycemic agent Antibodies to Insulin
Normal/Fasting <55 <200 <3 <5 >2.7 <25 - -
Exogenous Insulin <55 <200 >>3 <5 ≤2.7 >25 - -
Insulinoma <55 ≥200 ≥3 ≥5 ≤2.7 >25 - -
Nesidioblastosis
Post gastric bypass hypoglycemia (PGPH)
Insulin autoimmune hypoglycemia <55 >>200 >>3 >>5 ≤2.7 >25 - +
Oral hypoglycemic agent <55 ≥200 ≥3 ≥5 ≤2.7 >25 + -
IGF¤ <55 <200 <3 <5 ≤2.7 >25 - -

‡ Free C-peptide and proinsulin concentrations are low
¤ IGF= Insulin Growth Factor, Increased pro-IGF-2, free IGF-2, IGF-2/IGF-1 ratio


Differentiating hypoglycemia from other diseases that cause autonomic hyperactivity symptoms :

Disease Clinical Manifestation Investigations
Symptoms Signs
Palpitations Fever Sweating Headache
Hypoglycemia + - + +
Anxiety disorders + - + +
  • Patient looks irritable
  • Rapid pulse and may be irregular
  • Normal investigations
Pheochromocytoma + + + +
Arrhythmia + - - -
  • Irregular pulse
  • ECG changes according to the cause
Hyperthyroidism + + + +

References

  1. Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER; et al. (2009). "Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline". J Clin Endocrinol Metab. 94 (3): 709–28. doi:10.1210/jc.2008-1410. PMID 19088155.
  2. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P; et al. (2002). "Biochemical diagnosis of pheochromocytoma: which test is best?". JAMA. 287 (11): 1427–34. PMID 11903030.
  3. Bravo EL (1991). "Pheochromocytoma: new concepts and future trends". Kidney Int. 40 (3): 544–56. PMID 1787652.

Template:WH Template:WS